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Chapter I 
 
Polymer Micelles / Polyplexes for Gene Therapy  
 
Gene therapies have emerged as a part of the revolution in cell and molecular biology over 
the second half of the 20th century. While viral gene therapies represent the gold standard in terms 
of efficiency, therapeutic use of viruses remains shadowed by concerns with safety.  Due to the 
tremendous opportunity for gene therapies to impact medicine, there is great motivation to work 
toward safer and targeted viral vectors and to also carry out parallel efforts toward engineering 
more efficient nonviral systems that can achieve safe, efficacious gene therapy in humans. Many 
of the recent breakthroughs in nonviral gene therapy are a result of advances in materials science, 
chemistry, and engineering that have enabled the synthesis/fabrication of more homogeneous 
materials with an array of well-defined and tunable functionalities, in addition to the evolution of 
technologies for more rigorous characterization of chemical composition and biological 
interactions of nanomaterials. Taken together, rapid advances in materials synthesis and 
characterization, combined with tremendous progress in our ability to manipulate the genome and 
molecular-level and nanoscale phenomena, are predicted to yield clinically-relevant breakthroughs 
in nonviral gene therapies that provide new and improved treatments for some of our most 
challenging diseases. 
Nucleic acid-based drugs are sought for the replacement of missing, mutated, or deficient 
genes and for the suppression of gene expression by RNA interference (RNAi). Common classes 
of nucleic acid-based drugs include plasmid DNA (pDNA), messenger RNA (mRNA), short 
interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), miRNA inhibitors, 
peptide nucleic acids (PNA), RNA-based adjuvants, and clustered regularly interspaced short 
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palindromic repeats/Cas (CRISPR/Cas) gene editing systems. The most heavily investigated 
delivery strategies are those for pDNA and siRNA delivery. Gene replacement/addition is the more 
mature field but comes with the extra challenges associated with delivering pDNA into the nucleus 
and the limitation that plasmids often do not stably integrate and thus do not have high potential 
for curing chronic genetic diseases. By contrast, RNAi by siRNA only requires delivery into the 
cytosol where the RNA-induced silencing complex (RISC) machinery is located.  The activated 
RISC complex contains the antisense siRNA strand and mediates the recognition and subsequent 
enzymatic degradation of complementary mRNA. Both approaches require some common and 
disparate delivery considerations based on the desired intracellular pharmacokinetics. For instance, 
both require accumulation at the tissue compartment of interest and must cross the outer cell 
membrane. However, RNAi by siRNA will only require a carrier with endosomal escape 
mechanisms while gene augmentation/replacement achieved through delivery of pDNA requires 
intracellular trafficking into the nucleus. 
In general, three major delivery barriers are considered when developing polymeric 
nanoparticles for gene therapy: 1) preferential biodistribution to the site of action, 2) cellular 
internalization by the targeted cell type, and 3) trafficking to and unpackaging within the 
intracellular compartment where the nucleic acid cargo will be active (Figure 1). Viruses have 
evolved mechanisms to efficiently overcome these barriers and are the inspiration for the design 
of biomimetic polymer nanoparticles. Continued breakthroughs in the elucidation of the 
mechanisms of action of viruses, combined with rapid advances in synthetic fabrication and 
characterization of virus-mimetic polymeric nanoparticles, suggests that more safe and effective 
nonviral gene therapies will continue to emerge.  
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Figure 1. Schematic of the 3 major systemic and intracellular barriers to delivery of gene therapies. 
(1) The drug should be able to accumulate at the site of pathology, whether passively or by active 
targeting. (2) The drug should escape the circulation, navigate the ECM, and be internalized by 
the targeted cell types. (3) The drug should be trafficked to and released within the sub-cellular 
compartment where it is active. 
 
A few major classes of polymeric nanoparticles such as micelles/polyplexes, cross-linked 
micelles, polymersomes, and nanogels have all been utilized for overcoming the above listed 
barriers to systemic drug delivery. Each class of polymer nanoparticle has strengths and 
shortcomings and the biomedical application will typically dictate choice of material as well as the 
potential for successful clinical translation. Herein, we focus upon gene and drug delivery from 
self-assembled micelles/polyplexes. 
Micelles are self-assembling amphiphilic block copolymers with a core-shell (hydrophilic-
hydrophobic) architecture. They are typically assembled in aqueous solutions by methods such as 
dialysis, pH adjustment, and dropwise addition of concentrated organic solutions. The formation 
of core-shell architecture is driven by entropic processes, resulting in segregation of a hydrophobic 
core from solution by a hydrophilic outer corona. This is an attractive architecture for drug delivery 
applications because it is possible to load hydrophobic small molecule therapeutics into the 
hydrophobic micelle core. The hydrophilic outer shell is often composed of PEG and serves as an 
aide for increased blood circulation and reduced cytotoxicity.  In many gene therapy applications, 
the outer corona or the core are endowed with cationic functionalities that enable the electrostatic 
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packaging of nucleic acids.  Pre-assembled micelles with a cationic corona can be used to load 
nucleic acids, forming “micelleplexes”.  In other approaches, a diblock polymer with one core-
forming, cationic block and one neutral hydrophilic block (typically PEG) is assembled into 
PEGylated polyplexes, also known as polyion complex (PIC) micelles, upon mixing with anionic 
nucleic acid cargo. Physicochemical attributes such as size, shape, chemical composition, and 
charge are all important factors when considering the design of micelles as therapeutic carriers 
because they have profound effect on their effectiveness in overcoming in vivo delivery barriers. 
The earliest approaches to using micelles/polyplexes as non-viral gene vectors employed 
cationic, amine-rich polymers such as poly(ethyleneimine) (PEI), poly(2-(dimethylamino)ethyl 
methacrylate) (PDMAEMA), and poly(L-lysine) (PLys). The amines of this class of cationic 
polymers are used for three purposes: 1) condensation/nuclease protection of negatively charged 
nucleic acids, 2) enhanced cellular uptake, and 3) endosomolytic escape. The positively charged 
amines form electrostatic interactions with and efficiently condense nucleic acids. The overall 
positive surface charge of the resulting particles also drives cellular uptake through mechanisms 
which are not yet fully elucidated, but which are likely mediated through anionic, heparin sulfate 
proteoglycans present on cell surfaces.1, 2 After internalization, polymers with secondary and 
tertiary amines with pKa values at or just below pH 7 drive endosomolytic escape through the 
proton-sponge effect.3, 4  
Polyplexes formed of solely of cationic homopolymers have shown promise as in vitro 
transfection agents but have many translational issues.5 Their cationic charge causes cytotoxicity 
and limits their utility for systemic delivery. The cationic surface charge also causes aggregation 
with serum proteins and red blood cells, generally thought to be the reason for their eventual 
disproportionate accumulation in the capillary beds of the lungs, liver, and spleen and rapid 
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clearance by the RES.  In extreme cases, this can lead to rapid blockage of pulmonary capillaries 
and acute mortality in animal models. Therefore, cationic polymers are typically synthesized as 
diblock copolymers with hydrophilic polymers such as PEG and used to form PIC micelles.6 
Kataoka’s group pioneered the development of these micelles and their application as gene vectors. 
They used PEG-b-poly(Lysine) (PEG-PLA) as a diblock copolymer to condense DNAs and form 
PIC micelles that utilize PEGylation to shield their cationic component. Though PLys has a high 
pKa that limits its proton sponge and endosomal escape capacity, this approach has served as the 
basis for numerous subsequent designs that utilize polyion complex formation to produce stable, 
nucleic acid-loaded micelles. 
Micelle surface functionalization with targeting moieties can be beneficial for both 
PEGylated and non-PEGylated micelles. Stayton et al. employed this approach to their cationic 
micelles by conjugating folate for cancer cell targeting.7 They were able to exhibit folate receptor 
specific interaction of the folate conjugated micelles as well as in vitro gene knockdown, though 
this system is also not optimized for intravenous delivery due to high residual surface charge.  
More commonly, targeting moieties are added to the surface of PEGylated micelles. Kataoka et al. 
attached targeting molecules to their PEGylated PIC micelles for various applications.8 They 
attached lactose for targeting the ASGP receptor of HepG2 cells, showing a significant increase in 
cellular transfection efficiency compared with micelles lacking lactose.9 They also employed the 
cyclic RGD peptide as a means to target αvβ3 integrin receptors. This integrin is expressed on 
many cell types that play an important role in angiogenesis, and is a potentially useful means to 
target anti-angiogenic tumor therapies. In these studies, this targeting approach improved PIC 
micelle tumor delivery of pDNA encoding suicide genes.10 Hydrophobic stabilization of the core 
in PIC micelles has also been employed in order to achieve better pharmacokinetics in vivo.11 By 
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balancing cationic DMAEMA with hydrophobic BMA within the core of PEG-b-p(DMAEMA-
co-BMA) polyplexes, significantly higher endosomal escape and luciferase protein level 
knockdown was achieved in vitro. As a result of the improved stability and pharmacokinetics of 
this carrier system, it was able to produce knockdown of the model gene PPIB in vivo without any 
active targeting moiety. 
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Chapter II 
 
Combinatorial Library of Ternary Polyplexes Enables Identification of Improved siRNA 
Nanocarriers 
 
 
Abstract 
 A new library of ternary siRNA polyplexes formed of combinatorially combined pH-
responsive polymers was developed and screened for gene silencing efficacy in vitro and in vivo. 
[2-(dimethylamino)ethyl methacrylate] (DMAEMA)- and butyl methacrylate (BMA)-containing 
polymers were synthesized via reversible addition – fragmentation chain transfer (RAFT) 
polymerization. Ternary polyplexes were formed by varying the amounts and ratio of core-forming 
copolymers to corona-forming PEGylated, diblock copolymers during polyplex assembly. This 
library was developed such that structure-activity relationships of pH-responsive polymeric 
nanoparticles such as polyplex surface PEGylation density, size, stability, and endosomolysis 
could be systematically studied, and the relative importance of design parameters identified. The 
lead ternary polyplex formulation identified from multiparametric in vitro screening, DB-50B412, 
was optimally PEGylated with enough PEG to ensure colloidal stability (no change in size by DLS 
between 0 and 24 hr) and neutral surface charge (-1.86 mV) but had higher cell uptake (>90% 
positive cells) than the most densely PEGylated particles. The DB-50B412 polyplexes also 
incorporated the most hydrophobic and endosomolytic core-forming polymer, resulting in robust 
endosomolysis and in vitro siRNA silencing (~85% protein level knockdown) of the model gene 
luciferase. The potential efficacy of our lead ternary polyplex was further validated in vivo and 
benchmarked against binary polyplexes of the corona-forming PEGylated diblock. The DB-
50B412 polyplex exhibited a reduced level of renal clearance after intravenous administration, 
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resulting in enhanced pharmacokinetics (1.6-fold increased area under the curve (AUC)) and 
consequently increased enhanced permeation and retention (EPR)-driven tumor accumulation 
(2.6-fold higher) compared to binary polyplexes. The combined cell- and systemic-level delivery 
benefits achieved with DB-50B412 resulted in significantly better in vivo gene silencing in an 
orthotopic mammary tumor model after both intratumoral (54% protein level knockdown, 1 
injection) and intravenous (54% protein level knockdown, 3 injections) administration.  
 
Introduction 
 RNA interference (RNAi) was initially observed by Mello and Fire et al. in 199812, and 
soon thereafter siRNAs were confirmed as short double-stranded nucleic acid molecules capable 
of potent and highly specific inhibition by RNAi.13, 14 Currently, cellular and systemic delivery 
barriers limit the applications of siRNA.15  Naked siRNAs do not readily enter cells, have no 
inherent mechanism for endosome escape, and are rapidly cleared through filtration in the kidneys 
after systemic administration.16, 17 Thus, the use of siRNA as a safe and efficacious therapeutic is 
contingent upon its effective delivery to the desired tissue, cell type, and sub-cellular compartment 
of interest. To date, a variety of methodologies have been developed to overcome the challenge of 
siRNA delivery, including covalent modifications18, 19, antibody-protamine fusion20, liposomal 
encapsulation21, and nanoparticle formulations of cationic lipids or polymers.22-24 
 Packaging of siRNA by cationic nanoparticle formulations is one of the most investigated 
approaches.25, 26 By this approach, siRNA is packaged onto nanocarriers with a large excess of 
cationic charge which serves to drive cellular uptake through interaction with the anionic cellular 
membrane.27 Moreover, surface PEGylation has been widely employed as a strategy to neautralize 
these carriers for reduced opsonization and increased stealth from the mononuclear phagocyte 
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system (MPS) for systemic administration in vivo.28-30 However, merely cationic polyplexes, 
PEGylated for systemic administration, still suffer from a lack of stability in vivo. This class of 
polyplexes, formed by electrostatic interaction, are disassembled at the glomerular basement 
membrane (GBM) and cleared primarily through the kidneys, resulting in modest increases of 
circulation time over naked siRNA.31, 32 In previous work, we endeavored to improve the 
performance of cationic polyplexes through the incorporation of hydrophobicity into the core of 
the polyplex.11 This approach led to polyplexes with enhanced intracellular delivery of siRNA and 
improved in vivo bioactivity in the liver, kidneys, and spleen.  
 Efforts to develop effective siRNA transfection reagents by combinatorial approaches have 
been successful, yielding potent reagents that rival viral constructs. Green, Langer, Anderson, et 
al. have developed large libraries of poly(β-amino esters) (PBAEs) and lipid or lipid-like 
nanoparticles through combinatorial methods with great success. Green et al. initially developed a 
library of cationic PBAEs in which the lead reagents were able to achieve pDNA transfection 
comparable to adenoviruses33 and have more recently developed libraries which yielded PBAE 
derivatives highly effective at delivering siRNA and pDNA to glioblastomas.34, 35 Anderson and 
Langer have used combinatorial synthesis methods to develop large libraries of cationic lipid and 
lipid-like nanoparticles, reporting the most potent in vivo siRNA knockdown in multiple animal 
models to date.22, 36, 37 
 In this work, we expand upon previous findings showing the importance of hydrophobic 
stabilization of cationic polyplexes and use a combinatorial approach to systematically study 
important structure-function relationships of PEGylated siRNA polyplexes and yield a potent in 
vivo siRNA delivery reagent. Moreover, a multiparametric in vitro screening methodology was 
employed in order to optimize siRNA polyplexes for simultaneously overcoming cell-level 
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barriers (uptake/endosomal escape) and systemic barriers (stability for long circulation and 
reduced renal clearance) following intravenous administration.  
 Poly(2-(dimethylamino)ethyl methacrylate) (pDMAEMA, DM), poly[(2-
(dimethylamino)ethyl methacrylate)-co-(butyl methacrylate)] (p(DMAEMA-co-BMA), DB), 
poly[(ethylene glycol)-b-(2-(dimethylamino)ethyl methacrylate)] (PEG-b-p(DMAEMA), 0B), 
and poly[(ethylene glycol)-b-[(2-(dimethylamino)ethyl methacrylate)-co-(butyl methacrylate)]] 
(PEG-b-p(DMAEMA-co-BMA), 50B) were synthesized via RAFT polymerization. Ternary 
polyplexes were formed at varying N:P ratios (ratio of polymer amines:nucleic acid phosphates) 
and varying ratios of the core (DM/DB) to corona forming polymers (0B/50B) for three classes of 
formulations: DB core/0B corona [DB-0B], DB core/50B corona [DB-50B], and DM core/50B 
corona [DM-50B] to produce a library. This strategy affords surface charge neutral, siRNA core-
loaded polyplexes stabilized by electrostatic and hydrophobic interactions with the ability to 
rapidly tune the polyplex core-corona composition and degree of surface PEGylation. Through 
this ternary complex/combinatorial approach, we were able to systematically study important 
polyplex characteristics such as surface PEGylation density, size, stability, and endosomolysis. 
Ternary polyplexes which were optimized to overcome multiple barriers to siRNA delivery 
achieved the highest gene silencing and incorporation of the DB core was identified as a crucial 
parameter for achieving siRNA silencing in vitro. The lead ternary polyplex identified from 
multiparametric screens was validated in vivo, showing favorable pharmacokinetics, 
biodistribution, and efficiently accumulating in and achieving gene specific siRNA silencing in an 
orthotopic mammary tumor model.  
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Materials and Methods 
2.1 Materials. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
unless otherwise specified. DMAEMA and BMA monomers were passed twice through a basic 
alumina gravity column prior to use in order to remove inhibitors. 2,2-Azobis(2-
methylpropionitrile) (AIBN) was recrystallized twice from methanol. All cell culture reagents 
were purchased through Fischer Scientific unless otherwise specified. Cell culture media and 
reagents, including Dulbecco’s Modified Eagle Medium (DMEM), Fetal Bovine Serum (FBS), 
PBS (-/-), PBS (+/+), and gentamycin were purchased through Life Technologies (Grand Island, 
NY, USA).  
2.2 Synthesis of 4-Cyano-4-(ethylsulfanylthiocarbonyl)sulfanylpentanoic acid (ECT) and 
PEG-ECT macro-Chain Transfer Agent (macro-CTA). ECT, the RAFT CTA, was synthesized 
according to a previously reported procedure.38 The terminal carboxylic acid of ECT was then 
conjugated to PEG.11 Briefly, methoxy-PEG (2 mmol, 10 g, Mn = 5000 Da), ECT (4 mmol, 1.045 
g), and Dimethylaminopyridine (DMAP, 0.08 mmol, 10 mg) were dissolved in dry DCM (50 mL) 
and dicyclohexylcarbodiimide (DCC, 4 mmol, 0.82 g) was added while stirring. The reaction 
mixture was stirred for 48 h at RT. Precipitated cyclohexyl urea was removed by filtration. DCM 
layer was concentrated and precipitated into diethyl ether twice. The precipitated PEG-ECT was 
washed thrice with diethyl ether and dried under vacuum. 1H NMR (400 MHz Sprectrometer, 
Brüker, CDCl3) showed 84% ECT conjugation to PEG.  
2.3 Polymer Synthesis and Characterization. RAFT polymerization was used to synthesize 
all four polymers, either from ECT or the PEG-ECT macro-CTA. DMAEMA-co-BMA (DB) and 
pDMAEMA (DM) were synthesized from ECT (Figure 2a). In both cases, the target degree of 
polymerization was 150, reaction volume was 3 mL (Dioxane), degassing was done for 30 min by 
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nitrogen purge, and the polymerizations proceeded at 70 °C for 20 h using AIBN as an initiator at 
10:1 (CTA:AIBN) molar ratio. Reactions were stopped by removing the flask from heat and 
opening the reaction to air. The reaction mixtures were transferred to dialysis tubing and dialyzed 
one day against methanol and one day more against diH2O to remove unreacted monomers and 
ECT prior to lyophilization. PEG-b-pDMAEMA (0B) and PEG-b-p(DMAEMA-co-BMA) (50B) 
were synthesized from the PEG-ECT macro-CTA (Figure 2a). The target degrees of 
polymerization were 100 and 150, respectively. Reaction volumes were 3 mL (Dioxane), 
degassing was done for 30 min by nitrogen purge, the polymerizations proceeded at 70 °C for 20 
h, and AIBN was used as an initiator at 10:1 (macro-CTA:AIBN) molar ratio. Reactions were 
stopped by removing the flask from heat and opening the reaction to air. The resulting diblock 
copolymers were precipitated in a cold solution of pentane:diethyl ether (90:10). The isolated 
polymers were dried, re-dissolved in ethanol, dialyzed one day against diH2O and lyophilized to 
yield the final product. Polymers were characterized for composition and molecular weight (Mn) 
by 1H NMR (400 MHz Sprectrometer, Brüker, CDCl3). Absolute molecular weight and 
polydispersity (PI) were further determined by gel permeation chromatography (GPC) using DMF 
+ 0.1 M LiBr as the mobile phase with inline Agilent refractive index and Wyatt miniDAWN 
TREOS light scattering detectors. Serial dilutions (10 mg/ml – 0.25 mg/ml) in DMF were 
measured on a digital refractometer to determine dn/dc values for calculating absolute molecular 
weight on GPC.  
2.4 Assembly of siRNA loaded ternary polyplexes and size, zeta potential, and stability 
characterization. Three combinations of polymers were utilized for forming ternary polyplexes: 
DB-0B, DB-50B, and DM-50B. All polymers were dissolved in pH 4.0 citric acid buffer (10 mM). 
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Figure 2. Polymer synthesis and ternary polyplex formation. (A) Four single-pot reactions yield 
the DB, DM, 0B, and 50B polymer units for forming unique classes of ternary polyplexes. (B) 
Three major classes of ternary polyplexes (DB-0B, DB-50B, and DM-50B) formed in aqueous 
milieu by complexing with siRNA at pH 4.0 and subsequently raising the pH to drive polyplex 
assembly. 
 
siRNA was pre-condensed with the binary, core-forming polymer at each specified N:P ratio for 
30 min at 1 mg/ml polymer concentration. Next, differing amounts of ternary, corona-forming 
polymer were added in order to give the appropriate final N:P ratio and let complex for an 
additional 30 min. Polymer amounts needed to yield final N:P ratios were determined according 
to the following two equations for binary (1) and ternary (2) polyplexes: 
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(1)                                             𝑛𝑚𝑜𝑙 𝑃𝑜𝑙 =  
(𝑛𝑚𝑜𝑙 𝑁𝐴)(𝑏𝑝 𝑁𝐴)(2)(𝑁:𝑃)
(𝑅𝑈 𝐷𝑀𝐴𝐸𝑀𝐴)(0.5)
 
(2)                     𝑛𝑚𝑜𝑙 𝑃𝑜𝑙2 =  
(𝑛𝑚𝑜𝑙 𝑁𝐴)(𝑏𝑝 𝑁𝐴)(2)(𝑁:𝑃)−(𝑛𝑚𝑜𝑙 𝑃𝑜𝑙1)(𝑅𝑈 𝐷𝑀𝐴𝐸𝑀𝐴1)(0.5)
(𝑅𝑈 𝐷𝑀𝐴𝐸𝑀𝐴2)(0.5)
 
where nmol Pol is the nmol of binary polymer, nmol NA is the nmol of nucleic acid, N:P is the 
ratio of primary amines to phosphates, RU DMAEMA is the number of repeating units of 
DMAEMA within the polymer backbone, nmol Pol2 is the nmol of ternary, corona-forming 
polymer, nmol Pol1 is the nmol of binary, core-forming polymer, RU DMAEMA1 is the repeating 
units of DMAEMA within the binary, core-forming polymer backbone, and RU DMAEMA2 is 
the repeating units of DMAEMA within the ternary, corona-forming polymer. A 5-fold excess of 
pH 8.0 phosphate buffer (10 mM) was added to every sample before filtering through 0.45 μm 
pore syringe filters and measuring hydrodynamic diameter (Dh) and zeta potential (ζ) of the 
resulting ternary polyplexes at 0 and 24 h using dynamic light scattering (DLS) (Malvern Zetasizer 
Nano ZS, Malvern, UK). The naming scheme used for ternary polyplex formulations is as follows: 
[Binary Polymer]-[Ternary Polymer](Binary N:P)(Ternary N:P). For example, the lead ternary 
polyplex which contains a DB core formulated at 4:1 N:P and 50B corona formulated to a final 
N:P of 12:1 reads as DB-50B412.  
2.5 Characterization of pH-dependent membrane disruption by the hemolysis assay. The 
hemolysis assay was used to assess the potential for all ternary polyplex formulations to escape 
the endolysosomal pathway. Red blood cells (RBCs) were obtained from anonymous donors and 
isolated by a previously reported and well-established protocol.39 After isolation, RBCs were 
incubated with varying concentrations (5, 15, and 30 μg/ml) of each ternary polyplex formulation 
at four pH’s indicative of extracellular and endolysosomal ranges (7.4, 6.8, 6.2, 5.6). After 1 h of 
incubation, intact RBCs and any debris were centrifuged out, and supernatants were removed. The 
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supernatants were measured for absorbance at 451 nm (hemoglobin absorbance) and percent 
hemolysis was determined relative to 1% Triton-X100 detergent.  
2.6 Cell Culture. Human epithelial breast cancer cells (MDA-MB-231) and mouse 
embryonic fibroblasts (NIH3T3) were cultured in DMEM supplemented with 10% FBS and 50 
μg/mL gentamicin. MDA-MB-231 and NIH3T3 cells were transfected with Lentiviral Expression 
particles for firefly luciferase, Green Fluorescent Protein (GFP), and Blasticidin resistance 
resulting in the generation of luciferase expressing-MDA-MB-231 (L231) and NIH3T3 (L3T3) 
cell lines.  
2.7 Cytocompatability of ternary polyplexes. Cytocompatability of all formulations of 
ternary polyplexes was evaluated by adding scrambled siRNA containing ternary polyplexes to 
L231 and L3T3 cells and measuring relative cell number based on cellular luminescence. All 
polymers were dissolved in pH 4.0 citrate buffers (10 mM, 3.33 mg/ml) and binary, core-forming 
polymers were incubated with a siRNA for 30 min at the appropriate N:P ratio determined by 
equation (1) above. Next, the ternary, corona-forming polymer (10 mM, pH 4.0 citrate, 3.33 
mg/ml) was added in order to yield the appropriate final N:P ratio determined by equation (2) 
above and incubated for 30 min. A 5-fold excess of pH 8.0 phosphate buffer (10 mM) was then 
used to raise the solutions to pH 7.4. L231 and L3T3 cells were seeded to 96-well black-walled 
plates at a density of 2,000 cells/well and allowed to adhere overnight. Ternary polyplex 
formulations were then added to each well in full serum media (DMEM, 10% FBS, 50 μg/mL 
gentamicin) at a final siRNA concentration of 100 nM and incubated with the cells for 24 h. After 
24 h, media was replaced with luciferin containing media (150 μg/ml) and luminescence signal 
was collected on a Lumina III IVIS system (Xenogen Corporation, Alameda, CA, USA).  
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2.8 Cell uptake of ternary polyplexes. Cell uptake was evaluated in both MDA-MB-231 
and NIH3T3 cell types by flow cytometry. MDA-MB-231 and NIH3T3 cells were seeded to 24-
well plates at a density of 30,000 cells/well and allowed to adhere overnight. Ternary polyplexes 
were prepared by the same procedure above, substituting alexa488-labeled dsDNA for siRNA. 
Alexa488-dsDNA loaded ternary polyplexes were added to each well to give a final dsDNA 
concentration of 100 nM and incubated with cells in full serum media (DMEM, 10% FBS, 50 
μg/mL gentamicin) for 24 h. After 24 h, media with treatments was removed, cells were washed 
with PBS (-/-), trypsinized (0.25%), transferred to microcentrifuge tubes, and centrifuged at 420g 
for 7 min to yield a stable pellet of cells. Pellets were re-suspended in 0.4 mL PBS(-/-) with 0.04% 
trypan blue to quench extracellular fluorescence and monitored by FACS (FACSCalibur, BD 
Biosciences, Franklin Lakes, NJ, USA) at excitation wavelength of 488 nm and emission 
wavelength of 519 nm to quantify intracellular delivery of dsDNA.   
2.9 In vitro siRNA silencing by ternary polyplexes. The gene silencing profile of ternary 
polyplex formulations was screened within L3T3 fibroblasts. L3T3s were initially seeded in black-
walled, 96-well plates at a density of 2,000 cells/well and allowed to adhere overnight. Cells were 
then treated for 24 h in full-serum media (DMEM, 10% FBS, 50 μg/mL gentamicin) with all 
ternary polyplex formulations prepared as described above and containing an anti-luciferase 
siRNA sequence (100 nM). After 24 h, treatment media was replaced by luciferin containing media 
(150 μg/ml) and cellular luminescence was measured using an IVIS Lumina III imaging system 
(Xenogen Corporation, Alameda, CA, USA). The cells were then incubated for an additional 24 h 
after luciferin containing media was replaced by low-serum media (DMEM, 1% FBS, 50 μg/mL 
gentamicin). Cellular luminescence was re-measured at 48 h and normalized to a scrambled control 
siRNA sequence in all cases.  
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2.10 Ternary polyplex biodistribution and blood pharmacokinetics. Biodistribution in CD-
1 mice. Fluorescent polyplexes were formed as described above, with 0.1 mg/mL solution of binary 
polymer, by complexing with Cy5-labeled dsDNA at the optimal ternary N:P ratio (4:1/12:1 
Binary/Ternary) determined by in vitro screening. CD-1 mice (4-6 weeks old, Charles Rivers 
Laboratories, Wilmington, MA, USA) were injected via the tail vein with 1 mg/kg (dsDNA dose) 
of fluorescent polyplexes. After 20 min, animals were sacrificed and the organs of interest (heart, 
lungs, liver, spleen, and kidneys) were excised. The organs were fluorescently imaged and 
quantified on an IVIS Lumina III imaging system (Xenogen Corporation, Alameda, CA, USA) at 
excitation wavelength of 620 ± 5 nm and emission wavelength of 670 ± 5 nm (n = 6). 
Blood plasma pharmacokinetics. Blood was collected retro-orbitally at 5 min and 10 min 
post-injection, not exceeding two collections per animal. After 20 min, animals were sacrificed, 
and blood was immediately collected via the renal vein. Blood samples were centrifuged at 2000 
x g for 5 min and 5 μL of plasma was taken from the supernatant and diluted into 95 μL PBS (-/-
). Fluorescence was measured and quantified on an IVIS Lumina III imaging system (Xenogen 
Corporation, Alameda, CA, USA) at excitation wavelength of 620 ± 5 nm and emission 
wavelength of 670 ± 5 nm (n = 6). A standard curve was generated by measuring the fluorescence 
of the initial fluorescent polyplex solution in PBS (-/-) over the range of 200% - 1.5% of the 
injected dose. The standard curve was utilized in order to calculate the percent of injected dose in 
each blood sample, and the calculated values were used to determine siRNA concentration in the 
plasma at each time point as well as area under the curve (AUC) values.  
Biodistribution in athymic nude tumor-bearing mice. Athymic nude female mice (4-6 
weeks old, Jackson Laboratory, Bar Harbor, ME, USA) were injected in each mammary fat pad 
with 1 x 106 L231 cells in DMEM:Matrigel (50:50). After 17 days, tumor-bearing mice were 
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injected via the tail vein with 1 mg/kg (dsDNA dose) of fluorescent polyplexes. After 20 min, 
animals were sacrificed and the organs of interest (heart, lungs, liver, spleen, kidneys, and tumors) 
were excised. The organs were fluorescently imaged and quantified on an IVIS Lumina III imaging 
system (Xenogen Corporation, Alameda, CA, USA) at excitation wavelength of 620 ± 5 nm and 
emission wavelength of 670 ± 5 nm (n = 6). 
2.11 In vivo siRNA silencing by ternary polyplexes. Intratumoral (i.t.) siRNA silencing. 
Athymic nude female mice (4-6 weeks old, Jackson Laboratory, Bar Harbor, ME, USA) were 
injected in each mammary fat pad with 1 x 106 L231 cells in DMEM:Matrigel (50:50). After 17 
days, tumor-bearing mice were injected intraperitoneally (i.p.) with luciferin substrate (150 mg/kg) 
and imaged for bioluminescence on an IVIS Lumina III imaging system (Xenogen Corporation, 
Alameda, CA, USA) 20 minutes post-injection. Next, the mice were injected i.t. with 1 mg/kg 
(siRNA dose) polyplexes containing either anti-luciferase siRNA, a scrambled control siRNA, or 
saline. After 24 hours, the mice were re-injected with luciferin (150 mg/kg) and imaged for 
bioluminescence 20 min post-injection of luciferin. For quantification, the ratio of 
bioluminescence of anti-luciferase siRNA treated to scrambled siRNA treated tumors was 
determined within each mouse and the percent luciferase activity was calculated as: ratio at 24 
hr/ratio at 0 hr (n = 5).  
 Intravenous (i.v.) siRNA silencing. Athymic nude female mice (4-6 weeks old, Jackson 
Laboratory, Bar Harbor, ME, USA) were injected in each mammary fat pad with 1 x 106 L231 
cells in DMEM:Matrigel (50:50). After 17 days, tumor-bearing mice were injected i.p. with 
luciferin substrate (150 mg/kg) and imaged for bioluminescence on an IVIS Lumina III imaging 
system (Xenogen Corporation, Alameda, CA, USA) 20 minutes post-injection. Next, the mice 
were injected via the tail vein with 1 mg/kg (siRNA dose) polyplexes containing either anti-
19 
 
luciferase siRNA, a scrambled control siRNA, or saline. Mice were imaged and dosed at days 17, 
18, and 19 and imaged again on days 20 and 24. Relative luminescence was determined by 
measuring the raw luminescent intensity of each tumor on each day and comparing to the initial 
signal at day 17 (n = 6).  
 
Results and Discussion 
3.1 Polymer Synthesis and Characterization. The two core-forming, binary copolymers 
(DB and DM) and two shell-forming, ternary diblock copolymers (0B and 50B) were synthesized 
from either the RAFT CTA ECT or 5 kDa macro-CTA PEG-ECT, respectively (Figure 2a). RAFT 
polymerization is advantageous for the synthesis of biomacromolecules which require complex 
architectures with precise and monodisperse products.40, 41 All four polymers were synthesized 
with low polydispersity indices (Mw/Mn < 1.3) and resulted in products close to the targeted 
composition and molecular weight (Figures S2 and S3). Moreover, the simple and single-step 
polymerizations used herein are scalable and yield polymers which can be rapidly purified. These 
polymers were chosen as the base units of three distinct classes of core-shell ternary polyplexes 
(DB-0B, DB-50B, and DM-50B) which build on previous work showing that balancing cationic 
siRNA polyplexes with hydrophobicity can help overcome cell-level and systemic siRNA delivery 
barriers that limit the effectiveness of strictly cationic polyplexes.11, 42-44 Within each class, the 
amount of core-forming binary polymer, shell-forming ternary polymer, and the ratio of the two 
were varied in order to systematically study the effects of each component as well as investigate 
structure-function relationships such as surface PEGylation density, size, stability, endosomolysis, 
and composition of the resulting polyplexes in vitro and in vivo.  
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3.2 Physicochemical characterization of siRNA-loaded polyplexes. Polyplex size, surface 
zeta potential, and stability are crucial parameters when designing a systemic delivery system for 
siRNA.25 Optimal polyplexes have small size (20 – 50 nm) for enhanced tissue penetration45, 
neutral zeta potential for avoiding aggregation with serum proteins, opsonization, and detection 
and clearance by the MPS42, 46, and are colloidally stable for circulation in the blood plasma.47 
Thirty ternary polyplexes were formed from varying N:P ratios and varying ratios of the core- to 
corona-forming polymers within each class of ternary polyplex (DB-0B, DB-50B, and DM-50B) 
in order to generate a combinatorial library (Figure 2b). The library was initially screened for size 
at 0 h and 24 h and zeta potential by DLS to indicate which polyplexes were physicochemically 
optimal for systemic administration. DB-0B, DB-50B, and DM-50B ternary polyplexes all formed 
stable and significantly more compact polyplexes (~15 – 40 nm) than the 0B or 50B (~100 nm) 
binary polyplexes (Figure 3). Additionally, polyplex stability at 24 h was directly related to amount 
of corona-forming polymer and consequently the degree of surface PEGylation (Figures 3 and S4). 
As the degree of PEGylation was increased, a threshold was reached in each class where 
aggregation was prevented at 24 h and further PEGylation above the threshold showed no added 
benefit. The zeta potential for all polyplexes screened was between +5 and -5 mV, which is optimal 
for systemic administration. In sum, the initial physicochemical screening of this library of ternary 
polyplexes identified a subgroup of promising formulations with advantageous characteristics for 
effective siRNA delivery in vivo.  
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Figure 3. Size and zeta potential of library of ternary polyplexes consisting of all three classes of 
polyplexes at varying ratios of core- to corona-forming polymer.  
 
3.3 Characterization of pH-dependent membrane disruption. Entrapment in the 
endolysosomal pathway and subsequent degradation or trafficking out of the cell limit the 
effectiveness of many biologic drugs including siRNA.48, 49 The hemolysis assay was used as an 
initial indicator of the potential for ternary polyplexes to escape the endolysosomal pathway and 
deliver siRNA to the site of activity within the cytosol. Hemolysis was exhibited by all classes of 
ternary polyplexes investigated. However, ternary polyplexes which had 50B in the corona had 
more desirable hemolysis profiles than 0B corona polyplexes. The 50B-containing polyplexes 
showed switch-like endosomolytic behavior at the early endosomal pH 6.8, whereas 0B-containing 
polyplexes had weak hemolysis and exhibited hemolysis at the extracellular/physiological pH 7.4 
(Figure 4). The degree of hemolysis observed was also dependent upon the corona-forming 
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polymer. For the 0B corona, the degree of hemolysis decreased with increasing amounts of 0B 
polymer, indicating that the 0B polymer shielded the hemolytic DB core in a dose-dependent 
manner (Figure 4a). On the other hand, the degree of hemolysis was increased by adding increasing 
amounts of the 50B corona polymer (Figure 4b, c). This trend can be noticed by the hemolytic 
behavior at pH 6.8, which consistently increases as polyplexes contain more 50B corona-forming 
polymer. Therefore, ternary polyplexes which contained 50B as the corona-forming polymer 
exhibited optimal pH-dependent membrane disruptive behavior while 0B-corona ternary 
polyplexes exhibited sporadic hemolysis and in some cases showed hemolysis at pH 7.4, which 
we generally correlate with cytotoxicity.  
3.4 In vitro cytocompatibility and cellular uptake of ternary polyplexes. The 
cytocompatibility and relative cell uptake of all ternary polyplexes were initially screened in L3T3 
and NIH3T3 cells, respectively. The L3T3s, NIH3T3s which were made to constitutively express 
luciferase protein, offered the ability to quantify luminescence as a measure of cell number for 
determining cytocompatability. After 24 hours of incubation with polyplexes containing a 
scrambled control siRNA sequence, only the DB-0B class of polyplexes exhibited significant 
cytotoxicity compared to no treatment (Figure 5). The observed toxicity increased consistently as 
the amount of polymer was increased, and the polyplexes with the most DB core polymer (DB-
0B46 – 420) approached 100% toxicity (Figure 5a). This result correlates with the observation of 
membrane disruption at pH 7.4 for some formulations as indicated from the hemolysis assay. No 
DB-50B or DM-50B polyplexes were significantly toxic compared to no treatment (Figure 5b, c), 
again correlating well with the observation of controlled, switch-like membrane disruption at the 
early endosomal pH 6.8 from the hemolysis assay. 
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Figure 4. Hemolysis profiles of (A) DB-0B, (B) DB-50B, and (C) DM-50B ternary polyplexes.  
 
Further, binary polyplex formulations of DB (DB2B and DB4B) approached 100% toxicity 
without the addition of a corona-forming ternary polymer (Figure 5a, b), suggesting that the 
corona-forming polymer effectively coats the DB core and that there is a significant 
cytocompatability benefit of polyplex PEGylation. 
 Cellular uptake was dependent upon the chemistry of the cationic block of the corona-
forming ternary polymer as well as the ratio of the PEGylated, ternary and the core-forming, binary 
cationic polymers. DB-0B ternary polyplexes exhibited the highest cell uptake with up to 10-fold 
higher mean fluorescence intensity than DB-50B and DM-50B polyplexes (Figure 3d-f). However, 
DM-50B and DB-50B ternary polyplexes still exhibited up to 5-fold higher mean fluorescence 
intensity than their parent 50B binary polyplexes. The increasing fluorescence intensity observed 
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within the DM-50B51 – 58 polyplexes is due to incomplete complexing of the Alexa488-labeled 
dsDNA. The increasing intensity is observed as the polyplexes complex slightly more dsDNA for 
each increase in the final N:P ratio. In all other groups, a clear trend of decreasing cell uptake was 
observed for increasing degrees of PEGylation. After reaching an 8:1 final N:P ratio, each 
subsequent addition of more corona-forming PEGylated polymer significantly decreased cell 
uptake. Importantly, being able to control the amount of corona-forming polymer and thereby the 
density of PEGylation affords the ability to choose an optimal PEGylation state which provides 
colloidal stability and also a high level of cell uptake.  
 
 
Figure 5. Ternary polyplex screens for cell viability and uptake in mouse embryonic fibroblasts 
(3T3s). Percent cell viability of (A) DB-0B, (B) DB-50B, and (C) DM-50B polyplexes. Cellular 
uptake of (D) DB-0B, (E) DB-50B, and (F) DM-50B polyplexes.  
 
 
 3.5 In vitro siRNA silencing by ternary polyplexes. The classes of ternary polyplexes were 
evaluated for in vitro target silencing of the model gene luciferase in L3T3 cells. Both DB-0B and 
DB-50B classes of ternary polyplexes achieved significantly greater siRNA knockdown (measured 
as protein level expression of luciferase at 48 h and normalized to scrambled siRNA control) than 
26 
 
their parent 0B and 50B binary polyplexes, respectively (Figure S6), as well as the best previously 
published ternary complexes.50, 51 Although DB-0B polyplexes were taken up by cells up to 10-
fold more than other polyplex classes, the DB-50B46 – 420 group of ternary polyplexes achieved 
the greatest knockdown with between 65 – 85% reductions in luciferase activity at 48 hr (Figure 
S6). Therefore, the DB-50B46 – 420 group of polyplexes may overcome other intracellular barriers 
(such as endosomal escape) more efficiently in order to account for their high knockdown despite 
their lower levels of cell uptake.  
 3.6 Multiparametric evaluation of combinatorial library of ternary polyplexes. The 
combinatorial library herein investigated was developed with the motivation that polyplexes which 
successfully overcome multiple siRNA delivery barriers will achieve the greatest in vitro gene 
silencing while also being most rapidly translatable to in vivo models of disease. Therefore, assays 
were chosen which directly address physiological barriers to siRNA delivery and which would 
indicate polyplex ability to overcome each of these barriers. Size and stability (size at 24 h) were 
measured by DLS for indicators of tissue penetration (size) and stability in the blood (stability) 
and cell viability was measured for indicating extracellular inertness and cytocompatibility. Flow 
cytometry was used to quantify polyplex cell internalization. Hemolysis, the amount of core-
forming polymer, and whether the polyplex core contained DB were used to indicate 
endosomolytic capacity. Target gene silencing was used as a final readout to confirm the most 
effective polyplexes. As shown in Figure 6a, ternary polyplexes which perform best across 
multiple assays and which therefore overcome multiple delivery barriers achieve the greatest 
luciferase knockdown. Polyplex stability, cell uptake, and endosomolysis were further analyzed in 
order to determine the most important design parameters for achieving high siRNA knockdown. 
Stability was important for achieving knockdown, but it was not a perfect predictor as many 
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polyplexes which were stable did not achieve good knockdown and some polyplexes which were 
not stable did achieve knockdown (Figure 6b). In the same way, cell uptake was important for 
achieving knockdown, but many polyplexes which had close to 100% cell uptake did not achieve 
any knockdown. Finally, the presence of a DB core was one of the strongest indicators for 
achieving excellent gene knockdown. No polyplexes which did not contain the DB core achieved 
knockdown, whereas almost all polyplexes containing DB achieved knockdown. In sum, it was 
important to have polyplexes which were stable and had the highest uptake as prerequisites to 
achieving high knockdown, but the presence of the hydrophobic and endosomolytic DB core 
ensured a formulation which would effectively achieve gene knockdown. As a result of the 
multiparametric screen of our combinatorial library, the DB-50B46 – 420 class of polyplexes were 
identified as the most promising for in vivo translation. DB-50B412 was chosen as a lead candidate 
for in vivo testing because it possessed all good attributes of this class of polyplexes (stability, 
uptake, endosomolysis, and silencing) while using less material than DB-50B416 and DB-50B420 
formulations.  
3.7 Blood pharmacokinetics and biodistribution of lead ternary polyplexes. The lead 
ternary polyplex, DB-50B412, identified from multiparametric in vitro screening was tested in 
vivo in order to validate it as a potent siRNA nanocarrier for systemic delivery applications as well 
as validate that the multiparametric screening approach successfully resulted in a rapidly 
translatable reagent. The blood pharmacokinetics and biodistribution of DB-50B412 polyplexes 
were initially investigated in wild type CD-1 mice and benchmarked against the parent 50B binary 
polyplexes. Significantly higher amounts of fluorescence were detected in blood samples collected 
at each time point (5, 10 and 20 min) after tail vein injection of 1 mg/kg Cy5-dsDNA loaded 
polyplexes (Figure 7a).  
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Figure 6. Multiparametric analysis of ternary polyplexes. (A) A heat-map representative of 
polyplex performance in multiple assays which predict the ability to overcome physiological 
barriers. (B) Measures of stability, uptake, and endosomolytic potential plotted against in vitro 
luciferase activity. 
 
This led to a 1.6-fold increase in the area under the curve (AUC) value for DB-50B412 ternary 
polyplexes compared to 50B binary polyplexes. Passive tumor targeting is achieved by 
nanoparticles between ~20-200 nm through the enhanced permeation and retention (EPR) effect.52 
The amount of nanoparticles which are available to accumulate via the EPR effect is highly 
dependent upon the AUC of the nanoparticles, where nanoparticles which fall within the 
appropriate size range and have higher AUCs typically achieve more accumulation within 
tumors.52, 53 Therefore, the increased AUC of DB-50B412 ternary polyplexes is important for 
improving siRNA delivery to tumors.  
 The biodistribution of DB-50B412 ternary polyplexes to major organs of interest and 
tumors was investigated in both wild type CD-1 mice and tumor-bearing athymic nude mice after 
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17 days of tumor growth (~75 – 150 mm3). Consistent in both mouse models, the DB-50B412 
ternary polyplexes exhibited significantly lower fluorescent signal in the kidneys (Figure 7b, c). 
Recent studies have identified the kidneys as the major route for clearance of siRNA polyplexes 
which are assembled by electrostatic interactions.31, 32 In these studies, anionic proteoglycans such 
as heparin sulfate of the glomerular basement membrane were identified as the culprits for 
polyplex disassembly and subsequent rapid clearance through the kidneys. Therefore, it is 
important to reduce clearance through the kidneys as much as possible in order to achieve higher 
AUCs for i.v. administered siRNA polyplexes. In this case, DB-50B412 ternary polyplexes 
concomitantly exhibited a reduction in accumulation in the kidneys and increase in overall AUC 
when compared to their parent 50B binary polyplexes. Finally, DB-50B412 ternary polyplexes 
were detected at 2.6-fold higher levels in orthotopic tumors 20 min post-injection via the tail vein 
of 1 mg/kg Cy5-dsDNA loaded polyplexes (Figure 7c), consistent with the observed increase in 
AUC and principles of EPR-based tumor accumulation. In total, DB-50B412 polyplexes showed 
increased blood plasma AUC, reduced kidney accumulation, and increased tumor accumulation 
when compared to 50B binary polyplexes, all advantageous characteristics for effective systemic 
delivery of siRNA.  
3.8 In vivo siRNA silencing by ternary polyplexes. The siRNA silencing efficacy of lead 
DB-50B412 ternary polyplexes was evaluated in vivo in athymic nude mice bearing orthotopic 
L231 tumors in the mammary fat pad. In order to directly assess local silencing efficacy, we began 
by looking at silencing after i.t. injections of 1 mg/kg anti-luciferase siRNA loaded polyplexes. 
After allowing tumors to grow for 17 days to a final volume of 75 – 150 mm3, mice were injected 
i.t. in the right tumor with anti-luciferase siRNA loaded polyplexes and in the left tumor with 
scrambled siRNA loaded polyplexes as a contralateral control. 
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Figure 7. Blood pharmacokinetics and biodistribution of lead ternary polyplex. (A) Plasma 
concentration of siRNA and area under the curve (AUC) after tail vein injection of 1 mg/kg siRNA. 
(B) Ex vivo imaging and quantification of siRNA in major organs 20 min after tail vein injection 
of 1 mg/kg siRNA in CD-1 mice. (C) Ex vivo imaging and quantification of siRNA in major organs 
and tumors (2 per mouse) 20 min after tail vein injection of 1 mg/kg siRNA in tumor-bearing nude 
mice. 
 
Another cohort was injected i.t. with saline as a no treatment control. 50B binary polyplexes 
achieved 28% silencing (compared to scrambled, p = 0.62) while DB-50B412 ternary polyplexes 
achieved 54% silencing (compared to scrambled, p = 0.02) 24 hr after a single i.t. injection (Figure 
8a, b). The promising pharmacokinetics/biodistribution data along with achieving a significant 
local silencing effect motivated an attempt to achieve silencing after systemic (i.v.) administration 
as well. After tumors were allowed to grow for 17 days, 1 mg/kg anti-luciferase siRNA or 
scrambled siRNA loaded DB-50B412 ternary polyplexes were injected via the tail vein on days 
17, 18, and 19. A silencing effect was first detected on day 19, when the anti-luciferase group 
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exhibited 31% knockdown (p = 0.14) compared to the scrambled control. A statistically significant 
silencing effect was detected on day 20 with 44% (p = 0.04) knockdown, and the silencing was 
greatest at day 24 with 54% (p = 0.001) knockdown detected in anti-luciferase siRNA treated mice 
(Figure 8c). Efficacious in vivo gene silencing by DB-50B412 validated the functional importance 
of advantageous ternary polyplex design characteristics such as stability and endosomolysis of the 
DB core, increased cell uptake, increased blood plasma AUC, reduced renal clearance, and 
improved passive tumor accumulation by EPR.  
 
 
Figure 8. In vivo siRNA silencing of the model gene luciferase by ternary polyplexes. (A) 
Luciferase knockdown after i.t. injection of 1 mg/kg anti-luciferase siRNA, and representative 
images of luminescence after i.t. treatment with DB-50B412 ternary polyplexes. (C) Luciferase 
knockdown after i.v. injection (dosed on Day 0, 1, and 2) of 1 mg/kg anti-luciferase siRNA. 
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Conclusion 
 A combinatorial library of ternary polyplexes was developed and screened 
multiparametrically, providing new insights into the relative importance of various design 
variables for siRNA polyplexes and yielding a new siRNA nanocarrier optimized for in vivo 
delivery. The lead ternary polyplex, DB-50B412, had a balanced degree of PEGylation and 
incorporated the hydrophobically stabilized DB core-forming polymer for achieving colloidal 
stability with increased cell uptake, strong endosomolysis, and improved target gene silencing 
compared to binary polyplexes and other classes of ternary polyplexes. The DB-50B412 polyplex 
avoided renal clearance and stayed in circulation longer than binary polyplexes resulting in 
increased EPR-driven tumor accumulation. This combination of cell-level and systemic benefits 
led to increased in vivo gene silencing in orthotopic tumors after both local and systemic 
administration. Thus, our multiparametric screen successfully yielded a potent in vivo siRNA 
nanocarrier with validation in an orthotopic tumor model and further potential for active receptor-
ligand mediated targeting to a variety of specific pathologies.  
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APPENDIX 
 
Supplementary Figures 
 
Figure S1. Table of oligonucleotide sequences used throughout the studies. 
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Figure S2. 1H-NMR characterization of DM, DB, 0B, and 50B polymers used as base units of 
ternary polyplexes. 
 
 
 
Figure S3. Gel Permeation Chromatography (GPC) elugrams of DM, DB, 0B, and 50B polymers 
used as the base units of ternary polyplexes. 
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Figure S4. Comprehensive DLS spectra for (A) DB-0B, (B) DB-50B, and (C) DM-50B ternary 
polyplexes at 0 and 24 hr.  
 
 
Figure S5. Table of DLS size (0 and 24 hr) and zeta potential values. 
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Figure S6. In vitro luciferase gene silencing by ternary polyplexes. 
 
 
